

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A variant of a parent polypeptide comprising a human ~~IgG~~ IgG1 Fc region, which variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human effector cells more effectively, or binds an Fc gamma receptor III (FcγRIII) with better affinity, than the parent polypeptide and comprises two or more amino acid substitutions in the Fc region.
2. (original) The variant of claim 1 which comprises an antibody.
- 3.-4. (canceled)
5. (original) The variant of claim 1 which mediates ADCC about 1.5 fold to about 100 fold more effectively than the parent polypeptide.
6. (original) The variant of claim 1 which binds an FcγRII with better affinity than the parent polypeptide.
7. (original) The variant of claim 6 which further binds an FcγRII with worse affinity than the parent polypeptide.
8. (canceled)
9. (original) The variant of claim 1 which comprises at least one amino acid modification in a CH2 domain of the Fc region.
10. (currently amended) The variant of claim 1 which comprises at least one amino acid modification in the Fc region, other than ~~in a lower hinge region thereof~~ at amino acid positions 233 to 239.
11. (original) The variant of claim 1 which comprises an amino acid substitution at any one or more of amino acid positions 256, 290, 298, 312, 326, 330, 333, 334, 360, 378 or 430 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

12. (original) The variant of claim 11 which comprises two or more amino acid substitutions at the amino acid positions listed therein.

13. (original) The variant of claim 11 which comprises three or more amino acid substitutions at the amino acid positions listed therein.

14. (currently amended) A polypeptide comprising a variant Fc region which is not a native sequence Fc region and has with increased binding to an Fc gamma receptor (FcγR), which polypeptide comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 255, 256, 258, 265, 267, 268, 269, 270, 272, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 298, 301, 303, 305, 307, 312, 315, 324, ~~325~~, 327, 329, 330, ~~332~~, 335, 337, 338, 340, 360, 373, 376, 378, 382, 388, 389, 398, 414, 416, 419, 430, 434, 435, 437, 438 or 439 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

15. (original) The polypeptide of claim 14 wherein the variant Fc region comprises a variant human IgG Fc region.

16.-22. (canceled)

23. (currently amended) The polypeptide of claim 14 which displays increased binding to an FcγR and comprises an amino acid modification at any one or more of amino acid positions 255, 256, 258, 267, 268, 272, ~~276~~, 280, 283, 285, 286, 290, 298, 301, 305, 307, ~~309~~, 312, 315, ~~320~~, ~~322~~, ~~326~~, 330, ~~331~~, ~~333~~, ~~334~~, 337, 340, 360, 378, 398 or 430 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

24. (original) The polypeptide of claim 23 which displays increased binding to an FcγRIII.

25. (original) The polypeptide of claim 24 which further displays decreased binding to an FcγRII.

26. (currently amended) The polypeptide of claim 25 which displays increased binding to the FcγRIII and further displays decreased binding to the FcγRII, wherein the polypeptide comprises an amino acid modification at positions position 298 and/or ~~339~~ of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

27. (original) The polypeptide of claim 23 which displays increased binding to an FcγRII.

28. (currently amended) The polypeptide of claim 27 which displays increased binding to the FcγRII and comprises an amino acid modification at any one or more of amino acid positions 255, 256, 258, 267, 268, 272, ~~276~~, 280, 283, 285, 286, 290, 301, 305, 307, ~~309~~, 312, 315, ~~320~~, ~~322~~, ~~326~~, 330, ~~331~~, 337, 340, 378, 398 or 430 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

29. (original) The polypeptide of claim 27 which further displays decreased binding to an FcγRIII.

30. (original) The polypeptide of claim 29 which displays increased binding to the FcγRII and further displays decreased binding to the FcγRIII, wherein the polypeptide comprises an amino acid modification at any one or more of amino acid positions 268, 272, 298, 301, 322 or 340 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

31.-35. (canceled)

36. (original) A composition comprising the polypeptide variant of claim 1 and a pharmaceutically acceptable carrier.

37. (original) The composition of claim 36 which is sterile.

38.-49. (canceled)

50. (currently amended) A polypeptide comprising a variant Fc region with which is not a native sequence Fc region and has increased binding to an Fc gamma receptor (FcγR), which polypeptide comprises an amino acid modification at any one or more of amino acid positions 256, 290, 298, 312, ~~326~~, 330, ~~333~~, 360, 378 or 430 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

51. (previously presented) The polypeptide of claim 50 which comprises two or more amino acid substitutions at the amino acid positions listed therein.

52. (previously presented) The polypeptide of claim 50 which comprises three or more amino acid substitutions at the amino acid positions listed therein.

53. (previously presented) The polypeptide of claim 50 which comprises an antibody.

54. (previously presented) The polypeptide of claim 50 which comprises an amino acid substitution at position 298.

55. (canceled)

56. (currently amended) The polypeptide of claim 50 which comprises amino acid substitutions ~~at~~ at two or three of positions 298, 333 and 334.

57. (previously presented) The polypeptide of claim 56 which comprises amino acid substitutions at positions 298, 333, and 334.

58. (previously presented) The polypeptide of claim 57 which consists of amino acid substitutions at positions 298, 333, and 334.

59. (previously presented) The polypeptide of claim 50 which comprises a variant human IgG1, IgG2, IgG3 or IgG4 Fc region.

60. (previously presented) The polypeptide of claim 59 which comprises a variant human IgG1 Fc region.

61. (currently amended) A variant of a parent polypeptide comprising a human IgG Fc region, which variant binds an Fc gamma receptor TII (FcγRIII) with better affinity than the parent polypeptide and comprises two or more amino acid substitutions in the Fc region, wherein the Fc region of the variant is not a native sequence Fc region.